CD8A and neoplasm: The treatment of the estrogen-insensitive 4T1 syngeneic TNBC model with fulvestrant or JD128 in the presence of anti-PDL1 antibodies resulted in tumor growth suppression, a significant reduction in MDSC numbers, and increased numbers of anti-tumoral CD4+ and CD8+ T lymphocytes [24].